Bartell taps LexisNexis Risk Solutions, eRx Network for prescriber validation
SEATTLE — Bartell Drugs has become the first user of the strategic alliance between LexisNexis Risk Solutions and eRx Network for its prescriber validation. The pharmacy chain will leverage LexisNexis VerifyRx to perform real-time prescription compliance checks within their existing workflows.
"We were ready to take the next step in prescriber compliance and needed a turnkey solution that would not take resources away from our focus on patients," Bartell Drugs SVP pharmacy Peter Koo said. "The VerifyRx solution enables Bartell to take advantage of timely, accurate and comprehensive prescriber data via the LexisNexis Provider Data MasterFile, using eRx Network's connectivity to implement a solution directly within our pharmacy workflow."
VerifyRx lets pharmacies use the real-time connectivity of eRx Network and LexisNexis’ provider validation service on more than 8.5 million providers. It doesn’t require maintenance or IT integration efforts from the pharmacy chain, the companies said.
“We are pleased to be partnering with Bartell to deliver the vast capabilities of VerifyRx and the value provided by the seamless integration with the eRx Network,” LexisNexis Risk Solutions VP sales, pharmacy, Craig Ford said. “Verifying prescriber data in the workflow process is critical to pharmacies. Our strategic alliance has enabled us to respond to the needs of Bartell and other chains to deliver a leading, compliance-driven solution while using their existing connectivity.”
Other features include such risk mitigation features as a custom user interface and reporting tools.
"The combination of eRx Network's reliable network and the comprehensive prescriber compliance solution of LexisNexis Health Care will help make it easier and more efficient for Bartell to meet compliance requirements through its entire chain of stores," eRX Network SVP Richard Brook said. "We are confident that the implementation of our combined solutions will add value to Bartell's processes without causing any disruption to their workflows or increases to their operational costs or development efforts."
Dr. Reddy’s intros generic Renvela
HYDERABAD, India, and PRINCETON, N.J. — Dr. Reddy’s Laboratories recently launched its generic of Renvela (sevelamer carbonate) tablets. The drug is indicated to control serum phosphorus in adults and children ages 6 years and older with chronic kidney disease who are on dialysis.
“We are very pleased to bring Sevelamer Carbonate Tablets to market at this time,” Dr. Reddy’s EVP and head of North American generics Alok Sonig said. “This launch represents Dr. Reddy’s expertise and commitment to provide affordable alternatives for complex, limited-competition products to market.” This is the Company’s eighth overall and fourth limited-competition launch this fiscal year.
The Dr. Reddy’s generic is available in 800-mg dosage strength in 270-count bottles. For the 12 months ended July 2017, the drug had U.S. sales of roughly $1.88 billion, according to QuintilesIMS data.
Amazon reportedly still mulling online drug sales
Amazon is deciding how to get a foothold into the multibillion-dollar prescription drug market.
The online giant is expected to make a decision before Thanksgiving of whether it will sell prescription drugs online. These details came from an email from Amazon, as well as a source familiar with the situation, according to CNBC.
If Amazon moves forward with this new offering, the company will begin expanding its senior team with drug supply chain experts. This is in addition to the dozens of people it has already hired and consulted with regarding its potential move into the pharmacy market. Among them is Amazon’s consumables team’s VP, Eric French, the report said.
According to an anonymous source, Amazon is still evaluating — and aware of — the complexities this segment presents, CNBC reported.
To read more, click here.